AbbVie Inc. (ABBV) stock
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3086% above fair value
$286.01−6.81 (-2.33%)
Close on Nov 18, 2026Market cap $505.41BP/E 80.8Yield 2.33%
AbbVie gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
AbbVie's gross profit for the twelve months ending Jun 30, 2026 was $46.02B, up 11.2% year over year. For fiscal 2025 it was $42.96B, up 8.9% from the year before. Over ten years it grew 8.9% a year on average. The highest annual figure on record is $42.96B in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.96B | +8.9% |
| FY2024 | Dec 31, 2024 | $39.43B | +16.3% |
| FY2023 | Dec 31, 2023 | $33.90B | -16.6% |
| FY2022 | Dec 31, 2022 | $40.64B | +4.9% |
| FY2021 | Dec 31, 2021 | $38.75B | +27.4% |
| FY2020 | Dec 31, 2020 | $30.42B | +17.8% |
| FY2019 | Dec 31, 2019 | $25.83B | +3.2% |
| FY2018 | Dec 31, 2018 | $25.04B | +18.2% |
| FY2017 | Dec 31, 2017 | $21.17B | +6.9% |
| FY2016 | Dec 31, 2016 | $19.81B | +7.9% |
| FY2015 | Dec 31, 2015 | $18.36B | +18.2% |
| FY2014 | Dec 31, 2014 | $15.53B | +9.3% |
| FY2013 | Dec 31, 2013 | $14.21B | +2.4% |
| FY2012 | Dec 31, 2012 | $13.87B | +8.3% |
| FY2011 | Dec 31, 2011 | $12.81B | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.70B | +14.6% |
| Q1 FY2026 | Mar 31, 2026 | $10.78B | +15.4% |
| Q4 FY2025 | Dec 31, 2025 | $12.07B | +12.7% |
| Q3 FY2025 | Sep 30, 2025 | $10.47B | +2.2% |
| Q2 FY2025 | Jun 30, 2025 | $11.08B | +8.0% |
| Q1 FY2025 | Mar 31, 2025 | $9.34B | +13.7% |
| Q4 FY2024 | Dec 31, 2024 | $10.71B | +24.5% |
| Q3 FY2024 | Sep 30, 2024 | $10.25B | +37.7% |
| Q2 FY2024 | Jun 30, 2024 | $10.26B | +6.6% |
| Q1 FY2024 | Mar 31, 2024 | $8.22B | -0.3% |
| Q4 FY2023 | Dec 31, 2023 | $8.60B | -21.5% |
| Q3 FY2023 | Sep 30, 2023 | $7.44B | -24.0% |
| Q2 FY2023 | Jun 30, 2023 | $9.63B | -7.6% |
| Q1 FY2023 | Mar 31, 2023 | $8.24B | -13.1% |
| Q4 FY2022 | Dec 31, 2022 | $10.95B | +3.6% |
| Q3 FY2022 | Sep 30, 2022 | $9.79B | -1.6% |
| Q2 FY2022 | Jun 30, 2022 | $10.41B | +10.4% |
| Q1 FY2022 | Mar 31, 2022 | $9.49B | +7.8% |
| Q4 FY2021 | Dec 31, 2021 | $10.57B | +15.2% |
| Q3 FY2021 | Sep 30, 2021 | $9.95B | +26.7% |
| Q2 FY2021 | Jun 30, 2021 | $9.44B | +40.5% |
| Q1 FY2021 | Mar 31, 2021 | $8.80B | +31.8% |
| Q4 FY2020 | Dec 31, 2020 | $9.17B | +37.0% |
| Q3 FY2020 | Sep 30, 2020 | $7.85B | +19.7% |
| Q2 FY2020 | Jun 30, 2020 | $6.71B | +4.3% |
| Q1 FY2020 | Mar 31, 2020 | $6.68B | +8.9% |
| Q4 FY2019 | Dec 31, 2019 | $6.70B | +6.6% |
| Q3 FY2019 | Sep 30, 2019 | $6.56B | +2.5% |
| Q2 FY2019 | Jun 30, 2019 | $6.44B | +1.5% |
| Q1 FY2019 | Mar 31, 2019 | $6.13B | +2.1% |
| Q4 FY2018 | Dec 31, 2018 | $6.28B | +15.1% |
| Q3 FY2018 | Sep 30, 2018 | $6.40B | +19.0% |
| Q2 FY2018 | Jun 30, 2018 | $6.34B | +17.2% |
| Q1 FY2018 | Mar 31, 2018 | $6.01B | +22.0% |
| Q4 FY2017 | Dec 31, 2017 | $5.46B | +4.1% |
| Q3 FY2017 | Sep 30, 2017 | $5.38B | +9.2% |
| Q2 FY2017 | Jun 30, 2017 | $5.42B | – |
| Q1 FY2017 | Mar 31, 2017 | $4.92B | – |
| Q4 FY2016 | Dec 31, 2016 | $5.24B | – |
| Q3 FY2016 | Sep 30, 2016 | $4.93B | – |
See a number that looks wrong?